207 related articles for article (PubMed ID: 34774676)
1. SABR for High-Risk Prostate Cancer: A Prospective Multilevel MRI-Based Dose Escalation Trial.
Hannan R; Salamekh S; Desai NB; Garant A; Folkert MR; Costa DN; Mannala S; Ahn C; Mohamad O; Laine A; Kim DWN; Dickinson T; Raj GV; Shah RB; Wang J; Jia X; Choy H; Roehrborn CG; Lotan Y; Timmerman RD
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):290-301. PubMed ID: 34774676
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial.
Niazi T; Nabid A; Malagon T; Bettahar R; Vincent L; Martin AG; Jolicoeur M; Yassa M; Barkati M; Igidbashian L; Bahoric B; Archambault R; Villeneuve H; Tsui JMG; Mohiuddin M
Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):52-62. PubMed ID: 37224928
[TBL] [Abstract][Full Text] [Related]
4. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
[TBL] [Abstract][Full Text] [Related]
5. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
Zapatero A; Roch M; Castro Tejero P; Büchser D; Martin de Vidales C; González S; Rodríguez P; San Jose LA; Celada G; Murillo MT
Br J Radiol; 2022 Mar; 95(1131):20210683. PubMed ID: 34538073
[TBL] [Abstract][Full Text] [Related]
6. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity.
Ippolito E; Mantini G; Morganti AG; Mazzeo E; Padula GD; Digesù C; Cilla S; Frascino V; Luzi S; Massaccesi M; Macchia G; Deodato F; Mattiucci GC; Piermattei A; Cellini N
Am J Clin Oncol; 2012 Apr; 35(2):158-62. PubMed ID: 21336090
[TBL] [Abstract][Full Text] [Related]
7. Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial.
See AW; Bowden P; Wells G; Appu S; Lawrentschuk N; Liodakis P; Pandeli C; Aarons Y; Smyth LML; McKenzie DP
Radiat Oncol; 2022 Jul; 17(1):131. PubMed ID: 35879722
[TBL] [Abstract][Full Text] [Related]
8. Increased toxicities associated with dose escalation of stereotactic body radiation therapy in prostate cancer: results from a phase I/II study.
Hirata T; Suzuki O; Otani K; Miyake A; Tamari K; Seo Y; Isohashi F; Kai N; Hatano K; Fujita K; Uemura M; Imamura R; Tamenaga S; Yoshino Y; Fumimoto Y; Yoshioka Y; Nonomura N; Ogawa K
Acta Oncol; 2023 May; 62(5):488-494. PubMed ID: 37203203
[TBL] [Abstract][Full Text] [Related]
9. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial.
Sampath S; Frankel P; Vecchio BD; Ruel N; Yuh B; Liu A; Tsai T; Wong J
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):537-545. PubMed ID: 31733323
[TBL] [Abstract][Full Text] [Related]
12. Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.
Cloitre M; Valerio M; Mampuya A; Rakauskas A; Berthold D; Tawadros T; Meuwly JY; Heym L; Duclos F; Vallet V; Zeverino M; Jichlinski P; Prior J; Roth B; Bourhis J; Herrera FG
Br J Radiol; 2023 Apr; 96(1145):20220803. PubMed ID: 36745031
[TBL] [Abstract][Full Text] [Related]
13. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.
Hoffman KE; Voong KR; Pugh TJ; Skinner H; Levy LB; Takiar V; Choi S; Du W; Frank SJ; Johnson J; Kanke J; Kudchadker RJ; Lee AK; Mahmood U; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1074-84. PubMed ID: 24661661
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Feasibility Trial of Stereotactic Prostate Radiation Therapy With or Without Elective Nodal Irradiation in High-Risk Localized Prostate Cancer (SPORT Trial).
Houlihan OA; Redmond K; Fairmichael C; Lyons CA; McGarry CK; Mitchell D; Cole A; O'Connor J; McMahon S; Irvine D; Hyland W; Hanna M; Prise KM; Hounsell AR; O'Sullivan JM; Jain S
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):594-609. PubMed ID: 36893820
[TBL] [Abstract][Full Text] [Related]
15. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: a dose-escalation trial (DESTROY-4).
Deodato F; Ferro M; Bonome P; Pezzulla D; Romano C; Buwenge M; Cilla S; Morganti AG; Macchia G
Strahlenther Onkol; 2024 Mar; 200(3):239-249. PubMed ID: 38180492
[TBL] [Abstract][Full Text] [Related]
17. Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: Efficacy and Toxicity in the DELINEATE Trial.
Murray JR; Tree AC; Alexander EJ; Sohaib A; Hazell S; Thomas K; Gunapala R; Parker CC; Huddart RA; Gao A; Truelove L; McNair HA; Blasiak-Wal I; deSouza NM; Dearnaley D
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(4):715-724. PubMed ID: 31812718
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial.
Morris BA; Holmes EE; Anger NJ; Cooley G; Schuster JM; Hurst N; Baschnagel AM; Bassetti MF; Blitzer GC; Chappell RJ; Bayliss RA; Morris ZS; Ritter MA; Floberg JM
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):613-623. PubMed ID: 37179035
[TBL] [Abstract][Full Text] [Related]
19. SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation.
Alayed Y; Cheung P; Vesprini D; Liu S; Chu W; Chung H; Musunuru HB; Davidson M; Ravi A; Ho L; Deabreu A; D'Alimonte L; Bhounr Z; Zhang L; Commisso K; Loblaw A
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):36-41. PubMed ID: 30445172
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric Magnetic Resonance Imaging- Guided Dose-Escalated Radiation Therapy for Localized Prostate Cancer: A Prospective Phase 2 Trial.
Camden N; Blumenfeld P; Roy S; Chowdhary M; King K; Shors S; Braun R; White G; Turian J; Wang D
Pract Radiat Oncol; 2024; 14(2):e132-e140. PubMed ID: 37923137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
